Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
AFFiRiS AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AFFiRiS AG - Product Pipeline Review - 2014', provides an overview of the AFFiRiS AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of AFFiRiS AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of AFFiRiS AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of AFFiRiS AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the AFFiRiS AG's pipeline products Reasons to buy - Evaluate AFFiRiS AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of AFFiRiS AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the AFFiRiS AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of AFFiRiS AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of AFFiRiS AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of AFFiRiS AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 AFFiRiS AG Snapshot 5 AFFiRiS AG Overview 5 Key Information 5 Key Facts 5 AFFiRiS AG - Research and Development Overview 6 Key Therapeutic Areas 6 AFFiRiS AG - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Out-Licensed Products 10 Out-Licensed Products/Combination Treatment Modalities 11 AFFiRiS AG - Pipeline Products Glance 12 AFFiRiS AG - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 AFFiRiS AG - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 AFFiRiS AG - Drug Profiles 16 AD-02 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 IMMAD-04 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ATH-03 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PD-01 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 PD-03 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Vaccine for Chronic Kidney Disease 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Vaccine for Type 2 Diabetes 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Vaccine to Target Angiotensin II for Cardiovascular Diseases 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Vaccine to Target PCSK9 for Atherosclerosis 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Undisclosed Drug-1 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Undisclosed Drug-2 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 AFFiRiS AG - Pipeline Analysis 28 AFFiRiS AG - Pipeline Products by Target 28 AFFiRiS AG - Pipeline Products by Route of Administration 29 AFFiRiS AG - Pipeline Products by Molecule Type 30 AFFiRiS AG - Recent Pipeline Updates 31 AFFiRiS AG - Dormant Projects 33 AFFiRiS AG - Locations And Subsidiaries 34 Head Office 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 36 Disclaimer 36
List of Tables AFFiRiS AG, Key Information 5 AFFiRiS AG, Key Facts 5 AFFiRiS AG - Pipeline by Indication, 2014 7 AFFiRiS AG - Pipeline by Stage of Development, 2014 8 AFFiRiS AG - Monotherapy Products in Pipeline, 2014 9 AFFiRiS AG - Out-Licensed Products in Pipeline, 2014 10 AFFiRiS AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 11 AFFiRiS AG - Phase II, 2014 12 AFFiRiS AG - Phase I, 2014 13 AFFiRiS AG - Preclinical, 2014 14 AFFiRiS AG - Discovery, 2014 15 AFFiRiS AG - Pipeline by Target, 2014 28 AFFiRiS AG - Pipeline by Route of Administration, 2014 29 AFFiRiS AG - Pipeline by Molecule Type, 2014 30 AFFiRiS AG - Recent Pipeline Updates, 2014 31 AFFiRiS AG - Dormant Developmental Projects,2014 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.